An SPC, more formally written as SmPC, stands for Summary of Product Characteristics. It is a legal document approved alongside every medicine’s marketing authorization in the European Union and the United Kingdom. Think of it as the definitive reference sheet for a medication: it tells healthcare professionals exactly how a medicine should be used, what it treats, what side effects to expect, and who should avoid it.
Every prescription and non-prescription medicine authorized in the EU must have one. It is not written for patients directly, but it shapes nearly everything patients receive, from the leaflet inside a medicine box to the information a pharmacist shares at the counter.
What an SPC Contains
An SPC follows a standardized format with numbered sections so that any doctor, pharmacist, or nurse can quickly find what they need. The document covers the medicine’s name, its strength and form (tablet, injection, liquid), what conditions it is approved to treat, the recommended doses for different patient groups, and any situations where the medicine should not be used at all.
It also includes detailed safety information: known side effects listed by how common they are, interactions with other medicines, what happens in overdose, and whether the medicine is safe during pregnancy or breastfeeding. Further sections describe how the medicine works in the body, how it is absorbed, broken down, and eliminated, plus shelf life and storage instructions. For medicines used in patients with liver or kidney problems, the SPC specifies what adjustments are needed and what studies have been done in those groups.
Because it is a legal document, every claim a pharmaceutical company makes in advertising must be consistent with the SPC. If the SPC lists a medicine as approved for treating high blood pressure in adults, the company cannot market it for use in children unless the SPC is updated to reflect that.
Who Approves and Updates It
In the EU, the European Medicines Agency (EMA) oversees SPCs for medicines authorized through the centralized procedure. Its Committee for Medicinal Products for Human Use (CHMP) reviews and defines what goes into each section, including the exact wording of approved uses. For medicines authorized at a national level, coordination groups ensure consistency across member states. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) fulfills a similar role.
SPCs are not static. They are updated throughout a medicine’s entire lifespan as new safety or effectiveness data emerge. If post-marketing surveillance reveals a previously unknown side effect, or if a clinical trial supports a new use, the pharmaceutical company submits a revision. The relevant authority reviews and approves the change before the updated SPC becomes official. This means the SPC for a medicine that has been on the market for 20 years may look quite different from the version approved on day one.
SPC vs. the Patient Information Leaflet
The paper leaflet folded inside your medicine box is called the Patient Information Leaflet, or PIL. It draws its content from the SPC but is rewritten in simpler language and a more readable layout. EU law requires the PIL to be “easily legible” and “clearly comprehensible” for the general public, while the SPC is written for trained professionals and uses clinical terminology freely.
The SPC also contains far more technical detail than the PIL. It includes pharmacological data, full clinical trial results, and precise dosing adjustments that would overwhelm most patients but are essential for prescribers. The PIL, by contrast, focuses on what you need to know to take your medicine safely: common side effects, storage conditions, and when to seek help. Both documents serve a “full disclosure” function for side effects, but the SPC provides frequency data and context that the PIL simplifies.
How It Compares to the US Equivalent
The United States does not use SPCs. Instead, the FDA approves a document called Prescribing Information (sometimes called the Package Insert or PI). It serves a similar purpose, giving healthcare professionals the official reference for a medicine, but the two documents are far from identical.
A study comparing FDA Prescribing Information to EMA SPCs for twelve vaccines found that none were fully harmonized across all major categories. Even basic elements differed. The FDA might describe a vaccine’s approved use with one set of terms and age ranges, while the EMA’s SPC used different language and broader or narrower age limits. For one meningococcal vaccine, the FDA approved use from 2 months to 55 years of age, while the EMA’s SPC set the starting age at 2 years. A shingles vaccine’s EMA SPC listed prevention of both shingles and the nerve pain that can follow it, while the FDA version approved it only for preventing shingles and explicitly stated it was not for treating post-shingles pain.
Warnings, adverse events, and patient counseling information showed zero harmonization across all twelve vaccines examined. Pregnancy and pediatric assessments were the most aligned, matching for seven out of twelve products. These differences exist because each agency applies its own assessment criteria to the same clinical trial data, and there are currently no international guidelines requiring label content to match.
Where to Find an SPC
If you want to look up the SPC for a specific medicine, the most widely used public resource in the UK is the electronic Medicines Compendium (emc) at medicines.org.uk. It hosts up-to-date, approved SPCs and patient leaflets for licensed medicines, and it is free to search. For medicines authorized centrally in the EU, the EMA’s website publishes the full product information, including the SPC, for every medicine it has approved.
Pharmacists and doctors typically access these same databases when checking dosing, interactions, or contraindications. If you are a patient reading an SPC for the first time, keep in mind that the language is dense and clinical by design. The PIL that came with your medicine covers the same ground in plainer terms, so it is usually the better starting point unless you need the full technical picture.